When Will Mounjaro Be Approved for Sleep Apnoea — and What Should You Do Now?

What the current UK licence covers, and where sleep apnoea sits

Tirzepatide was approved by the MHRA for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition. Obstructive sleep apnoea is one of the conditions listed in that second category. So if you have been diagnosed with sleep apnoea and your BMI sits at 27 or higher, you may well meet the existing eligibility criteria for Mounjaro through the weight-management route already, you do not need to wait for a separate indication.

A dedicated look at Mounjaro and sleep apnoea covers the clinical relationship in more depth. The short version: excess weight around the neck and chest is a major driver of airway obstruction during sleep. Reducing that weight (through any effective method) tends to reduce both the frequency and the severity of apnoea events. The licensed weight-management pathway already captures this. For the full picture of what the licence currently says, this page on Mounjaro's current UK approvals is worth a read.

A US approval for a sleep apnoea indication (under the brand name Zepbound, which does not exist in the UK) was granted by the FDA in 2024 based on the SURMOUNT-CPAP trial. The MHRA makes its own independent assessments; no equivalent UK application outcome has been publicly announced. Regulatory timelines between the US and UK routinely differ.

The evidence behind the question, what trials actually showed

The SURMOUNT-CPAP trial enrolled adults with moderate-to-severe obstructive sleep apnoea who were also living with obesity. It measured the apnoea-hypopnoea index (AHI) (the number of breathing interruptions per hour) as its primary endpoint, not weight loss alone. At the 15mg maintenance dose over 52 weeks, tirzepatide produced a statistically significant reduction in AHI alongside substantial body-weight reduction. The trial concluded that the two effects were closely linked: weight drove the majority of the respiratory benefit.

That matters for how you think about timing. If the mechanism is largely weight-mediated, then starting treatment under the existing weight-management licence now and losing weight is likely to produce the same respiratory benefit you would be hoping for from a dedicated sleep apnoea approval. A separate MHRA indication would expand formal prescribing guidance and NHS commissioning pathways, it would not change the underlying biology. How tirzepatide's mechanism connects to sleep apnoea explains the pharmacology in plain terms.

NICE's appraisal of tirzepatide, published as TA1026 in December 2024, does not address a sleep apnoea-specific indication, it evaluates tirzepatide for weight management. Any future sleep apnoea submission to NICE would be a separate process.

What a future UK approval would (and would not) change

A dedicated UK sleep apnoea licence for tirzepatide would matter most for NHS commissioning. Currently, tirzepatide on the NHS is accessed via the weight-management pathway, which is rolling out in phases with strict eligibility criteria. A separate sleep apnoea indication could, in principle, create an additional route through respiratory or ENT services, though how quickly NICE would appraise it and how NHS England would commission it are separate questions with their own timelines.

For private prescribing, the practical difference may be smaller. Prescribers working within the existing weight-management licence can already prescribe for people with sleep apnoea who meet the BMI and comorbidity criteria. If you are considering the private route and want a realistic sense of what it costs, a comparison of Mounjaro pricing in the UK sets out what current private treatment looks like.

A new indication would also expand the clinical guidance available, clearer monitoring frameworks, AHI targets, and instructions for people who use CPAP machines alongside treatment. None of that exists formally in UK guidance yet. If you currently use a CPAP machine, tell your prescriber: they may want to monitor whether your settings need adjustment as your weight changes. Keep your pen in the fridge door alongside anything else you refrigerate each morning, a useful prompt for the weekly routine.

Making your decision: start now or wait?

This is exactly the kind of question a prescriber should help you answer, because the right choice depends on your specific BMI, your sleep apnoea severity, your other health conditions and your personal priorities. The framework, though, is straightforward.

If your BMI and comorbidities already meet the weight-management eligibility criteria, there is no clinical reason to wait for a hypothetical future licence. The medicine is the same; the dose schedule is the same; the evidence is the same. What changes with a separate indication is paperwork and NHS pathways, not the drug's effect on your airways. Whether Mounjaro can help your sleep apnoea specifically explores this in more detail.

If you are curious whether you meet the current criteria, the full eligibility picture for the weight-loss indication is the clearest starting point. The NHS medicines page for tirzepatide also sets out the licensed uses and key information from the patient leaflet.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, not a form processor. If sleep apnoea is part of your health picture, that context is relevant and our prescribers will factor it in. When you are ready to explore whether treatment is appropriate for you, start your free consultation, there is no obligation and no waiting list.